Search Results

AriBio Co., Ltd. announced authorisation from the European Medicines Agency for POLARIS-AD, a global, phase 3, early Alzheimer’s disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency on the Clinical Trial Authorisation of POLARIS-AD.

AriBio Co., Ltd. (AriBio) announces approval of the Investigational New Drug (IND) application by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the initiation of the Phase 3 Polaris-AD trial in China of AR1001 in early Alzheimer’s Disease (AD) on May 11th, 2024.

AriBio Co., Ltd. receives Notice of Acceptance for POLARIS-AD, a Phase 3 early Alzheimer’s disease clinical trial from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom.

Polaris Group announced that its board approved to increase the acquisition of Genovior Biotech’s shares to 100%.

AriBio Co., Ltd. announces the global expansion of the POLARIS-AD study, a phase 3 early Alzheimer’s disease trial into the European Union, United Kingdom, Korea and China.

Polaris Group, announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis.

Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).

Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with traditional chemotherapy as systemic treatment in the second or third line for LMS.